Cite
HARVARD Citation
Chen, H. et al. (2020). Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. Neuro-oncology advances. 2 (1), p. . [Online].